Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Missing lot numbers on the vial or the paperwork
Seek medical advice if diarrhoea persists beyond 7 days, contains blood or mucus, or accompanies severe abdominal pain or weight loss
It is often used for more widespread or systemic recovery needs
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
The information in this article is for educational purposes
This study aims to report the long-term treatment benefits of BoNT in initial responders with refractory neuropathic pain
US$ 23.09
US$ 25.18
US$ 26.49
US$ 23.78
US$ 23.71
